 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.  
         Underlining  indicates amendments to bill.  
         Strike out  indicates matter stricken from the bill by amendment or deleted from the law by 
amendment.  
         Italics indicate opposite chamber/confere nce committee amendments.             *hb0813*      
HOUSE BILL 813  
J5 EMERGENCY BILL  (5lr2785 ) 
ENROLLED BILL  
— Health and Government Operations/Finance  — 
Introduced by Delegates S.  Johnson and A.  Johnson , A. Johnson, Alston, Bagnall, 
Bhandari, Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez, 
Martinez, M.  Morgan, Pena –Melnyk, Reilly, Rosenberg, Ross, Szeliga, 
Taveras, White  Holland, Woods, and Woorman  
 
Read and Examined by Proofreaders:  
 
_______________________________________________  
Proofreader.  
_______________________________________________  
Proofreader.  
 
Sealed with the Great Seal and presented to the Governor, for his approval this  
  
_______ day of _______________ at _________________ _______ o’clock, ________M.  
  
______________________________________________  
Speaker .  
 
CHAPTER ______  
 
AN ACT concerning  1 
 
Pharmacy Benefits Administration – Maryland Medical Assistance Program and 2 
Pharmacy Benefits Managers   3 
Maryland Insurance Administration and Maryland Department of Health – 4 
Workgroup to Study Pharmacy Benefits Managers  5 
 
FOR the purpose of altering the reimbursement levels for drug products that the Maryland 6 
Medical Assistance Program is required to establish and that pharmacy benefits 7 
managers that contract with a pharmacy on behalf of a managed care organization 8 
are required to reimburse the pharmacy; altering the definition of “purchaser” for 9 
purposes of certain provisions of law regulating pharmacy benefits managers  to 10 
include certain insurers, nonprofit health service plans, and health maintenance 11 
organizations  requiring the Maryland Insurance Administration and the Maryland 12 
2 HOUSE BILL 813   
 
 Department of Health , in consultation with the Prescription Drug Affordability 1 
Board,  to con vene a workgroup to study certain issues related to pharmacy benefits 2 
managers and report to certain committees on or before a certain date ; and generally 3 
relating to pharmacy benefits administration  a workgroup to study pharmacy 4 
benefits managers . 5 
 
BY r epealing and reenacting, with amendments,  6 
 Article – Health – General  7 
Section 15 –118(b)  8 
 Annotated Code of Maryland  9 
 (2023 Replacement Volume and 2024 Supplement)  10 
 
BY adding to  11 
 Article – Health – General  12 
Section 15 –118(f)  13 
 Annotated Code of Maryland  14 
 (2023 Replacement Volume and 2024 Supplement)  15 
 
BY repealing and reenacting, with amendments,  16 
 Article – Insurance  17 
Section 15 –1601(s)  18 
 Annotated Code of Maryland  19 
 (2017 Replacement Volume and 2024 Supplement)  20 
 
BY adding to  21 
 Article – Insurance  22 
Section 15 –1632 23 
 Annotated Code of Maryland  24 
 (2017 Replacement Volume and 2024 Supplement)  25 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 26 
That the Laws of Maryland read as follows:  27 
 
Article – Health – General  28 
 
15–118. 29 
 
 (b) (1) [Except ] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION A ND 30 
EXCEPT  as provided under paragraph [(2)] (3) of this subsection, the Program shall 31 
establish [maximum ] MINIMUM reimbursement levels for the drug products for which 32 
there is a generic equivalent authorized under § 12 –504 of the Health Occupations Article [, 33 
based on the cost of the generic product ]. 34 
 
  (2) EXCEPT AS PROVIDED IN  PARAGRAPH (4) OF THIS SUBSECTION , 35 
MINIMUM REIMBURSEMEN T LEVELS ESTABLISHED  UNDER PARAGRAPH (1) OF THIS  36 
SUBSECTION SHALL BE AT LEAST EQUAL TO TH E NATIONAL AVERAGE DRUG  37 
 HOUSE BILL 813  3 
 
 ACQUISITION COST OF THE GENERIC P RODUCT  PLUS THE FEE –FOR–SERVICE  1 
PROFESSIONAL DISPENS ING FEE DETERMINED B Y THE DEPARTMENT IN  2 
ACCORDANCE WITH THE MOST RECENT IN –STATE COST –OF–DISPENSING SURVEY . 3 
 
  [(2)] (3) [If] EXCEPT AS PROVIDED IN  PARAGRAPH (4) OF THIS  4 
SUBSECTION , IF a prescriber directs a specific brand name drug, the reimbursement level 5 
shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the 6 
brand name product PLUS THE FEE –FOR–SERVICE PROFESSIONAL  DISPENSING FEE  7 
DETERMINED BY THE DEPARTMENT IN ACCORDA NCE WITH THE MOST RE CENT  8 
IN–STATE COST –OF–DISPENSING SURVEY . 9 
 
  (4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION D O NOT APPLY TO : 10 
 
   (I) A PHARMACY OWNED BY OR  UNDER THE SAME CORPO RATE  11 
AFFILIATION AS A PHA RMACY BENEFI TS MANAGER ; OR 12 
 
   (II) A MAIL ORDER PHARMACY . 13 
 
 (F) THE PROVISIONS OF § 15–1632  OF THE INSURANCE ARTICLE APPLY TO  14 
A MANAGED CARE ORGAN IZATION THAT USES A PHARMACY BENEFITS MA NAGER TO  15 
MANAGE PRESCRIPTION DRUG COVERAGE BENEFI TS ON BEHALF OF THE MANAGED  16 
CARE  ORGANIZATION . 17 
 
Article – Insurance  18 
 
15–1601.  19 
 
 (s) (1) “Purchaser” means a person that offers a plan or program in the State, 20 
including the State Employee and Retiree Health and Welfare Benefits Program,  AN 21 
INSURER , A NONPROFIT HEALTH S ERVICE PLAN , OR A HEALTH MAINTENANCE  22 
ORGANIZATION , that:  23 
 
  [(1)] (I) provides prescription drug coverage or benefits in the State; and  24 
 
  [(2)] (II) enters into an agreement with a pharmacy benefits manager for 25 
the provision of pharmacy benefits management services.  26 
 
  (2) “PURCHASER ” DOES NOT INCLUDE A N ONPROFIT HEALTH  27 
MAINTENANCE ORGANIZA TION THAT : 28 
 
   (I) OPERATES AS A GROUP MODEL ; 29 
 
   (II) PROVIDES SERVICES SO LELY TO A MEMBER OR PATIENT OF  30 
THE NONPROFIT HEALTH  MAINTENANCE ORGANIZA TION ; AND  31 
4 HOUSE BILL 813   
 
  
   (III) FURNISHES SERVICES THROUGH THE INTERNAL  PHARMACY  1 
OPERATIONS OF THE NO NPROFIT HEALTH MAINT ENANCE ORGANIZATION . 2 
 
15–1632.  3 
 
 A PHARMACY BENEFITS MA NAGER THAT CONTRACTS  WITH A PHARMACY ON  4 
BEHALF OF A MANAGED CARE ORGANIZATION , AS DEFINED IN § 15–101 OF THE  5 
HEALTH – GENERAL ARTIC LE, SHALL REIMBURSE THE PHARMACY AN AMOUNT  6 
THAT IS AT LEAST EQU AL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST 7 
PLUS THE FEE –FOR–SERVICE PROFESSIONAL  DISPENSING FEE DETER MINED BY THE  8 
MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE  9 
PROGRAM  IN ACCORDANCE WITH T HE MOST RECENT IN –STATE  10 
COST–OF–DISPENSING SURVEY . 11 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency 12 
measure, is necessary for the immediate preservation of the public health or safety, has 13 
been passed by a yea and  nay vote supported by three –fifths of all the members elected to 14 
each of the two Houses of the General Assembly, and shall take effect from the date it is 15 
enacted.  16 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 17 
That the Maryland Insurance  Administration and the Maryland Department of Health , in 18 
consultation with the Prescription Drug Affordability Board,  shall:  19 
 
  (1) convene a workgroup of interested stakeholders, including community 20 
pharmacies from both chain and independent settings, ph armacy services administrative 21 
organizations , health insurance carriers, plan sponsor representatives, drug wholesalers 22 
and distributors, non –pharmacy benefit manager –owned mail order pharmacies, brand 23 
name and generic drug manufacturers , pharmacists, phar macy benefits managers, and 24 
managed care organizations , and third –party experts in the field of drug pricing in 25 
Medicaid;  26 
 
  (2) review reimbursement for pharmacists, including:  27 
 
   (i) existing Maryland Medical Assistance Program requirements for 28 
pharmacy  benefits managers and managed care organizations related to dispensing fee 29 
reimbursement, pharmacy benefits managers fees charged to pharmacies and the 30 
Maryland Medical Assistance Program, transparency in pricing and reimbursement data, 31 
specialty drug des ignations, and appeals processes;  32 
 
   (ii) how other states’ pharmacy benefits services operate in 33 
Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia;  34 
 
 HOUSE BILL 813  5 
 
    (iii) measures that offset the Department’s costs to fund the Medicaid 1 
Managed Care Program and adopt NADAC plus the Fee –for–Service Professional 2 
Dispensing, including:  3 
 
    1. savings associated with NADAC ingredient cost pricing 4 
and managed care organizations; and  5 
 
    2. pharmacy benefits managers administrative fee 6 
consolidation and rebate allocations; and  7 
 
   (iv) strategies for adopting pharmacy reimbursement parity and 8 
drug pricing transparency;  9 
 
  (3) review coverage requirements for specialty drugs, including:  10 
 
   (i) which drugs are considered specialty for purposes of formularies 11 
across carriers and pharmacy benefits managers; and  12 
 
   (ii) what these drugs have in common for purposes of developing a 13 
new definition for “specialty drug”;  14 
 
  (4) review ERISA exemptions for pharmacy benefits management 15 
regulati on, including:  16 
 
   (i) the scope of Rutledge v. Pharmaceutical Care Management 17 
Association and subsequent case law and federal guidance;  18 
 
   (ii) how other states have responded to the Rutledge decision; and  19 
 
   (iii) what, if any, other State laws should  be amended;  20 
 
  (5) review the costs associated with pharmacies contracting with 21 
commercial plans versus pharmacies contracting with the Maryland Medical Assistance 22 
Program;  23 
 
  (6) review provisions of State law regarding pharmacy benefit managers, 24 
special ty pharmacies, and anti –steering, including:  25 
 
   (i) § 15–1611.1 of the Insurance Article related to the use of specific 26 
pharmacies or entities and the effect the section has on pharmacy costs in the fully insured 27 
market; and  28 
 
   (ii) § 15–1612 of the Insurance Article related to reimbursement and 29 
the effect the section has on pharmacy costs in the fully insured market;   30 
 
  (5) (7) on or before December 31, 2025, submit an interim report on their 31 
findings and recommendations to the Senate Finance Commit tee and the House Health 32 
6 HOUSE BILL 813   
 
 and Government Operations Committee, in accordance with § 2 –1257 of the State 1 
Government Article; and  2 
 
  (6) (8) on or before December 31, 2026, submit a final report on their findings 3 
and recommendations to the Senate Finance Comm ittee and the House Health and 4 
Government Operations Committee, in accordance with § 2 –1257 of the State Government 5 
Article.  6 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June 7 
1, 2025.  8 
 
 
 
 
Approved:  
________________________________ ________________________________ ________________   
           Governor.  
________________________________ ________________________________ ________________   
         Speaker of the House of Delegates.  
________________________________ ________________________________ ________________   
                 President of the Senate.  